NFKB1 and chronic kidney disease: Given that CKD has persistent chronic low-grade inflammation [67], moreover, Klotho could inhibit NF-κB inflammatory pathway activation and monocyte inflammatory factor release [56], so we have further reason to believe that the main negative regulatory pathway through which Klotho exerts its protective effect in CKD is the inflammatory response.